P17.02 RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC

Category Primary study
JournalJournal of Thoracic Oncology
Year 2021
This article has no abstract
Epistemonikos ID: 43496861a8646e8f31a769f57467f8d231d3346a
First added on: Feb 13, 2025